# Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

> **NCT01069796** · PHASE2 · TERMINATED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 64 (actual)

## Conditions studied

- Triple Negative Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01069796
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2012-03
- **Final completion:** 2014-06
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** The number of inclusion was reached normally
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069796, "Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01069796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*